Market Research Logo

Intermittent Claudication - Pipeline Review, H2 2015

Intermittent Claudication - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Intermittent Claudication - Pipeline Review, H2 2015’, provides an overview of the Intermittent Claudication’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Intermittent Claudication, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Intermittent Claudication and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Intermittent Claudication
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Intermittent Claudication and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Intermittent Claudication products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Intermittent Claudication pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Intermittent Claudication
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Intermittent Claudication pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Intermittent Claudication Overview
Therapeutics Development
Pipeline Products for Intermittent Claudication - Overview
Pipeline Products for Intermittent Claudication - Comparative Analysis
Intermittent Claudication - Therapeutics under Development by Companies
Intermittent Claudication - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Intermittent Claudication - Products under Development by Companies
Intermittent Claudication - Companies Involved in Therapeutics Development
Cytokinetics, Inc.
DNAVEC Corporation
Kowa Company, Ltd.
LTT Bio-Pharma Co., Ltd.
Nuo Therapeutics, Inc.
Pluristem Therapeutics Inc.
Intermittent Claudication - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALD-301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DVC1-0101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
K-134 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LT-0101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLX-PAD - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tirasemtiv - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Intermittent Claudication - Recent Pipeline Updates
Intermittent Claudication - Dormant Projects
Intermittent Claudication - Discontinued Products
Intermittent Claudication - Product Development Milestones
Featured News & Press Releases
Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications
Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea
Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel
Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study
Jul 08, 2013: Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells
Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study
Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany
Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells
Aug 13, 2012: Pluristem Moves Intermittent Claudication Indication Forward in Germany Through Collaboration With Cato Research
Jul 18, 2012: Pluristem Partners With CPC Clinical Research For Peripheral Artery Disease Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Intermittent Claudication, H2 2015
Number of Products under Development for Intermittent Claudication - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Intermittent Claudication - Pipeline by Cytokinetics, Inc., H2 2015
Intermittent Claudication - Pipeline by DNAVEC Corporation, H2 2015
Intermittent Claudication - Pipeline by Kowa Company, Ltd., H2 2015
Intermittent Claudication - Pipeline by LTT Bio-Pharma Co., Ltd., H2 2015
Intermittent Claudication - Pipeline by Nuo Therapeutics, Inc., H2 2015
Intermittent Claudication - Pipeline by Pluristem Therapeutics Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Intermittent Claudication Therapeutics - Recent Pipeline Updates, H2 2015
Intermittent Claudication - Dormant Projects, H2 2015
Intermittent Claudication - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Intermittent Claudication, H2 2015
Number of Products under Development for Intermittent Claudication - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report